

| Numéro de catalogue | DS856018 |
|---|---|
| Description |
Afasevikumab ELISA Kit (DS856018) — Quantitative sandwich ELISA for Afasevikumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml.
Highlights
|
| Type d'échantillon | Plasma, Serum |
| Sensibilité | 0.156 μg/ml |
| Plage | 0.31-5 μg/mL |
| Numéro d'accès | Q16552 & Q96PD4 |
| Applications | ELISA |
| Méthode de détection | Colorimetric |
| Type de test | Quantitative |
| Retraitement | 80-120% |
| Expédition | 2-8 ℃ |
| Stabilité et stockage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Spécifications | Afasevikumab |
| Noms alternatifs | MCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110, 1589503-30-9 |
| Contexte | Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified. |
| Note | For Research Use Only. |

Standard Curve of Afasevikumab ELISA Kit
Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.
Courrier : [email protected]


+86-027-65523339
Bâtiment C, No. 666, Rue Shendunsi, Wuhan, 430206, Chine
中文
English
한국어
日本語
Español
Français
Русский